Copper IUD Users May Have Lower Risk of High-Grade Cervical Neoplasms
Copper intrauterine device users were found to have a lower risk of high-grade cervical neoplasms compared with levonorgestrel-releasing intrauterine system users. (Source: CancerNetwork)
Source: CancerNetwork - March 19, 2020 Category: Cancer & Oncology Authors: Hannah Slater Source Type: news

Copper Intrauterine Devices Tied to Lower Risk for Cervical Cancer
WEDNESDAY, March 18, 2020 -- Use of copper intrauterine devices (Cu IUDs) is associated with a lower risk for cervical cancer versus use of the levonorgestrel-releasing intrauterine system (LNG-IUS), according to a study published in the February... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - March 18, 2020 Category: Pharmaceuticals Source Type: news

Columbia study evaluates cervical cancer risks of IUDs
(Data Science Institute at Columbia) Patients who used copper intrauterine devices were found to have a lower risk of cervical cancer compared to users of the levonorgestrel-releasing intrauterine system. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - March 10, 2020 Category: Cancer & Oncology Source Type: news

Researchers Make Progress Toward a Monthly Birth Control Pill
Birth control pills are among the most effective ways to prevent pregnancy, but only if women faithfully take them every day. Human nature being what it is, nearly half of women admit to missing a pill at least once every three months, and, as a result, about 9% of women on oral contraception become pregnant every year. That number would almost certainly fall if women only had to remember to take the pill once a month or so. That’s why researchers at MIT and Brigham and Women’s Hospital (with support from the Gates Foundation) are trying to create a once-a-month birth control pill. In a paper published today (...
Source: TIME: Health - December 4, 2019 Category: Consumer Health News Authors: Alice Park Tags: Uncategorized Birth Control embargoed study Reproductive Health Source Type: news

Dr. Wayne Bardin, 85, Innovative Researcher on Birth Control, Dies
He helped develop long-acting implanted contraceptive devices — like Norplant, Jadelle and Mirena — used by millions of women around the world. (Source: NYT Health)
Source: NYT Health - November 14, 2019 Category: Consumer Health News Authors: Knvul Sheikh Tags: Bardin, Dr. C. Wayne Deaths (Obituaries) Birth Control and Family Planning Abortion Drugs Population Council Research Drugs (Pharmaceuticals) Source Type: news

Medical News Today: How does the Mirena coil affect menopause?
The Mirena coil is a hormonal intrauterine device, or IUD, that many women use to prevent pregnancy. However, it can affect some symptoms of perimenopause. Find out more. (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - November 5, 2019 Category: Consumer Health News Tags: Women's Health / Gynecology Source Type: news

FDA Approves Liletta (levonorgestrel-releasing intrauterine system) to Prevent Pregnancy for up to Six Years
SAN FRANCISCO and DUBLIN October 28, 2019– Medicines360, a global nonprofit organization with a mission to expand women’s access to quality medicines, and Allergan plc (NYSE: AGN), a leading global pharmaceutical company, announced that... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - October 28, 2019 Category: Drugs & Pharmacology Source Type: news

The Lancet: First randomised trial finds no substantial difference in risk of acquiring HIV for three different forms of contraception
(The Lancet) A randomised trial of more than 7,800 African women found that a type of contraceptive injection (intramuscular depot medroxyprogesterone acetate -- DMPA-IM) posed no substantially increased risk of HIV acquisition when compared with a copper intrauterine device (IUD) and a levonorgestrel (LNG) implant. The results of this first ever randomised trial in the area, published in The Lancet, counter 30 years of epidemiology research suggesting a potential association between some types of contraceptives and risk of acquiring HIV. (Source: EurekAlert! - Infectious and Emerging Diseases)
Source: EurekAlert! - Infectious and Emerging Diseases - June 13, 2019 Category: Infectious Diseases Source Type: news

Why having the coil may make women anxious and depressed
The potential problems are being attributed to progestin — a synthetic form of progesterone — which is used in hormonal coils, including leading brands Mirena and Levosert. (Source: the Mail online | Health)
Source: the Mail online | Health - April 29, 2019 Category: Consumer Health News Source Type: news

Hundreds of women claim their IUD gave them a neurological disorder
There have been 856 lawsuits filed against Bayer by women who say that its popular IUD contraceptive, Mirena, cause them a neurological disorder, but one Columbia University expert says it's not so. (Source: the Mail online | Health)
Source: the Mail online | Health - December 7, 2018 Category: Consumer Health News Source Type: news

FDA approves five-year hormonal contraceptive
Allergan (NYSE:AGN) and the nonprofit women’s health pharma company Medicines360 said today that the FDA approved an application to extend the duration of use for Liletta for the prevention of pregnancy for up to five years. Medicines360 first won approval for the levonorgestrel-releasing intrauterine device in February of 2015. The system’s latest FDA approval is based on a review of additional efficacy and safety data from an ongoing Phase III trial. The Access IUS trial, which includes 1,751 women across the U.S., found that Liletta is more than 99% effective in preventing pregnancy for up to five years in a rang...
Source: Mass Device - October 16, 2018 Category: Medical Devices Authors: Sarah Faulkner Tags: Clinical Trials Drug-Device Combinations Food & Drug Administration (FDA) Pharmaceuticals Regulatory/Compliance Wall Street Beat Allergan Medicines360 Source Type: news

FDA Approves Medicines360's sNDA for LILETTA(R) (levonorgestrel-releasing intrauterine system) 52 mg to Prevent Pregnancy for up to Five Years
DUBLIN and SAN FRANCISCO, Oct. 16, 2018 -- (Healthcare Sales & Marketing Network) -- Allergan plc (NYSE: AGN), a leading global pharmaceutical company, and Medicines360, a global nonprofit women's health pharmaceutical company with a mission of expanding ... Biopharmaceuticals, Drug Delivery, FDA Medicines360, Allergan, LILETTA, levonorgestrel, contraceptive (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - October 16, 2018 Category: Pharmaceuticals Source Type: news

FDA Approves Liletta (levonorgestrel-releasing intrauterine system) 52 mg to Prevent Pregnancy for up to Five Years
DUBLIN and SAN FRANCISCO October 16, 2018 – Allergan plc (NYSE: AGN), a leading global pharmaceutical company, and Medicines360, a global nonprofit women’s health pharmaceutical company with a mission of expanding access to quality medicines,... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - October 16, 2018 Category: Drugs & Pharmacology Source Type: news

Medical News Today: Which is the best IUD for me?
The best IUD for each person depends on many factors. People can choose between hormonal IUDs, which include Mirena and Kyleena, and nonhormonal IUDs, such as ParaGard. In this article, we take a look at the benefits and risks of different types of IUD. (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - October 2, 2018 Category: Consumer Health News Tags: Birth Control / Contraception Source Type: news